Navigation Links
Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action

SALT LAKE CITY, June 14, 2007 /PRNewswire/ -- Prolexys Pharmaceuticals and announced today a publication describing the properties of the selective small molecule anti-tumor agent, erastin. Prolexys and Columbia applied the company's chemi-proteomics technology to understand the mechanism of action of erastin. The results, to be published in the June 14, 2007 issue of the journal Nature reveal that erastin binds to mitochondrial voltage- dependent anion channels (VDACs) -- a novel target for anti-cancer drugs. Knock-down of VDAC2 and VDAC3 gene expression causes resistance to erastin, implicating the involvement of these two proteins in erastin-mediated cell death. Treatment of cells with erastin results in VDAC-protein-mediated mitochondrial dysfunction, release of oxidative species and, ultimately, cell death. This process has a degree of selectivity for cells with aberrantly active RAS pathway. In normal cells, RAS pathway is involved in growth and differentiation of cells; however the aberrant activation of this pathway results in uncontrolled tumor growth.

Dr. Brent Stockwell, currently an Associate Professor of Biological Sciences and of Chemistry at , identified erastin as a small molecule anti-cancer agent that exhibits lethality in human tumor cells with mutations in RAS-related cancer genes such as HRAS, KRAS or BRAF, beginning when he was a Fellow at the Whitehead Institute for Biomedical Research. In February 2005, Prolexys signed an exclusive licensing agreement with the Massachusetts Institute of Technology, as the licensing agent of , and the Whitehead Institute, which provides Prolexys with exclusive, worldwide rights to a patent estate covering selective anti-tumor compounds in the erastin family. "This paper demonstrates that it is feasible to discover compounds that produce cancer-cell-selective toxicity and to use these to understand cell death mechanisms in cancer cells; furthermore,
'"/>




Page: 1 2 3

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:10/9/2008)...lts Expected in November 2008, BOTHELL, Wash., Oc...(Amex: DDD ) announced today the completion of pa...hree pivotal trials to evaluate the safety and,eff...se (ER) ibuprofen for,the over-the-counter (OTC) m...lts from this pivotal trial in November 2008. Ibup...
(Date:10/8/2008)...8 /PRNewswire-USNewswire/ -- The facts are,overwhe.../AIDS in,sub-Saharan Africa. More than 35,000,000 ...e already died of AIDS. The Foundation for Hospice...ying and their families,find compassion and relief...tive partnering initiative links African hospices ...
(Date:10/8/2008)...e Pioneers Research That May Offer New Hope to,Hea... -- Nationally, over 3,000 people are,waiting for ...y, only half,of those will receive a transplant. N... (AHI) is paving the way for how to treat congesti...timedia News Release, go to:, http://www.prnewswir...
(Date:10/8/2008)...o evaluate TAXUS(R) Element(TM) Platinum Chromium ...ss., Oct. 8 /- Boston Scien...at it has completed enrollment in,the PERSEUS tria...tion,TAXUS(R) Element(TM) paclitaxel-eluting coron...ed nearly 1,500 patients at 100 U.S. and,internati...
Breaking Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4LS9 Inc the Renewable Petroleum Company 28TM 29 Adds Key Positions to Executive Team and Scientific Advisory Board 3073 1LS9 Inc the Renewable Petroleum Company 28TM 29 Adds Key Positions to Executive Team and Scientific Advisory Board 3073 2Innovative eHealth Course to Take Place March 28 30 in Boston Massachusetts 11142 1Innovative eHealth Course to Take Place March 28 30 in Boston Massachusetts 11142 2Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 11138 1Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 11138 2Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 11138 3Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 11138 4Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 11138 5Tropical soils impede landmine detection 2134 1Tropical soils impede landmine detection 2134 2
...mboEmbolism (VTE) is Reduced by a,Significant 43% ...xane(R) / Lovenox(R), BRIDGEWATER, N.J., April 20,...ounced the publication of the PREVAIL (Prevention,...parin) trial in,the April 21st issue of The Lancet...administration of Clexane(R) / Lovenox(R),(enoxapa...
... Clinical Potential of Peregrine,s,Unique Selectiv...,Avastin(R) in Animal Cancer Models, TUSTIN, Calif...ine Pharmaceuticals, Inc. , a clinical stage,bioph...l antibodies,for the treatment of cancer and hepat...rom multiple studies presented at the recent,Cente...
Other Medicine Technology:The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 2The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 3The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 4The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 5The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7
(Date:10/12/2008)... Birdstep Technology,s high availability embedded ...carrier grade OSE RTOS. , ...Technology (OSE: BIRD) today announced the release...ing system. This is the latest platform to be adde...d platforms., , ,"We recognized the importanc...
(Date:10/11/2008)...ould Not Pose Setback and Expects the 89-Year-Old ... ASHEVILLE, N.C., Oct. 11 /PRNewswire/ -- Evangeli...in Montreat, N.C. upon his release this,afternoon ...g a brief stay.,He was admitted for observation af... late Friday., Mr. Graham,s physicians said that ...
(Date:10/11/2008)...ernational Transcends Cultural Divides, JOHANNESB...frican and,international audiences welcome Bishop ...fying gathering, which for the first time is being...tp://www.newscom.com/cgi-bin/prnh/20081011/CLSA011...off with performances by,South Africa,s own multi-...
(Date:10/10/2008)... those already on drugs, some diagnoses could be w...althDay News) -- A new study questions the commonl...e ( C. difficile ) infections are always preceded ...iversity and the Jewish General Hospital found tha...cquired C. difficile infections before hospitali...
Breaking Medicine News(10 mins):Health News:Birdstep Technology Adds ENEA's OSE RTOS to the List of Operating Systems Supported by Their RDM Server, Embedded Database Product 2Health News:Billy Graham Returns Home Following Hospital Observation 2Health News:Bishop T.D. Jakes Electrifies South Africa 2Health News:Antibiotics May Not Cause Diarrheal Bacteria 2
...yan governmment said Tuesday the rate of HIV/AIDS ...e still posed a a major challenge in the country....CC) said the rate fell from 6.1 percent in 2004 to...nt of the country's nearly 35 million people. "Of...
...etic version of a molecule found in the egg cells ...provide the world with the first drug treatment fo...es the sugary coating found on a tumour cell and b... invading the cell and inactivating the RNA it con...
...s is understood as the perception of noise in the ...nal source of sound, without any vibratory cochlea...rnal noise is produced). It is estimated that bet...uffered tinnitus at some time in their lives, acco...
...t study has found that a substance derived from th...rtain kinds of cancer cells. The study, conducte...ested that this substance could lead to a novel tr...mmon type of lung cancer. The compound, called be...
Other Medicine News:Health News:Brain Tumor Drug in Frogs A New Report 2Health News:Tinnitus Patients can Lead a Normal Life 2Health News:Tinnitus Patients can Lead a Normal Life 3Health News:Tinnitus Patients can Lead a Normal Life 4Health News:Tinnitus Patients can Lead a Normal Life 5Health News:Tree Bark Substance may Hold New Lung-cancer Treatment 2
Restylane is a gel of hyaluronic acid generated by,Streptococcus species of bacteria, chemically crosslinked,with BDDE, stabilized and suspended in phosphate,buffered saline at pH = 7 and concentrati
SCULPTRA™ is an injectable implant that contains microparticles of poly-L-lactic acid, a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. SCULPTRA is reconsti
The HEMOCHRON Response is a whole blood coagulation monitoring instrument designed to be used at the point-of-care. The Response includes an easy-to-read screen and data management features, includin
Minimizes imperfections and reduces the visible appearance of cellulite and stretch marks. This formula refines uneven skin texture and improves skin firmness and elasticity to leave you with skin yo
Medicine Products: